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Abstract. Serum matrix metalloproteinase-2,9 activity, galectin-3 and systemic inflammation in patients with 
postinfarction heart failure with preserved ejection fraction. Kuryata O., Zabida A., Sirenko O. The available 
data suggest that heart failure (HF) after myocardial infarction (MI) is a very frequent event. Recent meta-analysis 
showed that restrictive mitral filling pattern, the most severe form of diastolic dysfunction, was presented in 
approximately 10% of the patients with preserved ejection fraction. In addition, restrictive pattern was associated with 
poor outcome. However, the true prevalence and relevance of diastolic dysfunction after MI remains to be elucidated. 
Objective: study was designed to evaluate the serum level of MMP-2,9, galactin-3 and C-reactive protein (C-RP) in 
postinfarction heart failure with preserved ejection fraction (HFpEF) patients. Methods: We divided all included 
patients into two main groups: 1st group – 20 patients with HFpEF and history of myocardial infarction. 2nd group – 18 
patients with HFpEF and stable angina. Standard laboratory blood tests for erythrocyte sedimentation rate (ESR), C-
RP, haematological parameters, lipid profile, glucose, renal and liver function tests were performed and calculated 
body mass index (BMI) for all patients. MMP activity assay and galectin-3 serum level was detected for all patients. 
Results: It was established significant differences between study groups in MMP-2, MMP-9 levels. Particularly, 
patients with HFpEF with MI in anamnesis had significantly higher MMP-2, MMP-9 levels on 21.8% and 20.7% 
respectively. The C-RP and leucocytes levels were significantly higher in 1st group pts. Significant differences in MMP-
2, MMP-9 were established in 1st group patients in different age groups (p<0.05) (tab. 3). The MMP 2 level was 
positively correlated with MMP 9 level (R=0.73, p<0.05), the MMP 9 level – with age (R=0.68, p<0.05). There were 
no significant differences between galectin-3 level in study group. But we estimated significant differences in galectin-3 
level between 1st and 2nd subgroups (p<0.05). Conclusion: Serum MMP-2, MMP-9, CRP and galactin-3 were 
significantly increased in pts with postinfarction heart failure with preserved ejection fraction compare to pts without 
myocardial infarction in anamnesis. 
 
Реферат. Рівень матричних металопротеїназ-2,9, галектину-3 та системне запалення у хворих з пост-
інфарктною серцевою недостатністю зі збереженою фракцією викиду. Курята О.В., Забіда А., Сіренко О.Ю. 
Літературні дані свідчать, що серцева недостатність (CH) після перенесенго інфаркту міокарда (ІМ) є 
частою подією. Однак поширеність і фактори виникнення діастолічної дисфункції лівого шлуночка після 
перенесеного ІМ залишаються маловивченими. Мета: оцінити рівні сироваткових MMP-2,9, галактину-3 та С-
реактивного білка (СРП) при постінфарктній серцевій недостатності зі збереженою фракцією викиду. 
Матеріали та методи: у дослідження включено 38 пацієнтів з СН зі збереженою фракцією викиду віком від 40 
до 80 років: 1 група (n=20) з перенесеним інфарктом міокарда в анамнезі, 2-а група (n=18) пацієнтів зі 
стабільною стенокардією. Виконано стандартні лабораторні аналізи крові, визначення CРП, гематологічних 
параметрів, ліпідного профілю, глюкози, креатиніну. Визначення активності ММP та рівня галактину-3 в 
сироватці крові проводилось усім пацієнтам. Результати: пацієнти з ХСН з ІМ в анамнезі мали достовірно 
вищий рівень ММP-2, ММР-9 на 21,8% та 20,7% відповідно (р<0,05). Рівні CРП та лейкоцитів були достовірно 
вищими в пацієнтів 1-ї групи (р<0,05). Достовірні відмінності рівней ММП-2, ММP-9 встановлені в пацієнтів з 
перенесеним ІМ у різних вікових групах (р<0,05). Рівень MMP-2 позитивно корелював з рівнем MMP-9 (R=0,73, 
p<0,05), рівень ММР-9 – з віком (R=0,68, р<0,05). Встановлені достовірні відмінності між рівнем галектину-3 
серед пацієнтів різного віку (p<0,05). Висновок: сироваткові рівні MMP-2, MMP-9, CРП та галектину-3 були 
достовірно вищі у хворих з постінфарктною серцевою недостатністю зі збереженою фракцією викиду 
порівняно з пацієнтами без інфаркту міокарда в анамнезі. 
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The available data suggest that heart failure (HF) 
after myocardial infarction (MI) is a very frequent 
event [10]. Recent meta-analysis showed that restric-
tive mitral filling pattern, the most severe form of 
diastolic dysfunction, was presented in approximately 
10% of the patients with preserved ejection fraction. 
In addition, restrictive pattern was associated 
with poor outcome [9, 10]. However, the true preva-
lence and relevance of diastolic dysfunction after MI 
remains to be elucidated. Another important issue is 
that the consequences of cardiac dysfunction after 
MI are well established, and its presence increases 
the risk of death by at least 3- to 4-fold [9]. 
The endothelium may also be central to the pa-
thophysiology of heart failure, with endothelial cell 
damage or dysfunction that is probably more evident 
than that from vascular disease alone [1, 2, 3]. Cer-
tainly, heart failure is associated with abnormalities 
of thrombogenesis, leading to an increase in 
thrombosis related complications in this condition 
[10]. In HF, myocardial ischaemia features promi-
nently (even in dilated cardiomyopathy) and seve-
rely depressed myocardial blood flow is a predictor 
of poor prognosis [15]. 
Left ventricular (LV) regional remodelling is a 
continuous process that last for months to years after 
the acute injury and which will eventually lead to the 
development of HF. Matrix metalloproteinases 
(MMPs) and tissue inhibitor metalloproteinase 
(TIMPs) continue to have an important role in the 
process of chronic LV remodelling [12, 15]. 
A region specific portfolio of MMPs is induced 
after MI and is accompanied by a decline in TIMP 
levels, indicative of a loss of MMP-inhibitory 
control. MMP-1 and MMP-9 levels are significantly 
reduced within the border and MI regions at 8 weeks 
post-MI, whereas MMP-2 levels increases substan-
tially within the border and MI regions [15], sug-
gesting that MMP-9 mainly is associated with early 
post-MI events [12, 16]. In contrast to the acute MI 
setting, a different set of MMPs emerges at 8 weeks 
after MI. Interestingly, MMP-8, localized to neu-
trophils, is increased by over 6-fold within the bor-
der and MI regions at 8 weeks after MI, suggesting 
that MMP-8 is associated with a more chronic in-
flammatory response [6, 12, 16]. The levels of the 
collagenase MMP-13, and MT1-MMP are increased 
by nearly 3-fold in both border and MI region 8 
weeks post-MI [15]. MMP-3 is reduced within the 
MI region and MMP-7 falls within the border and 
MI regions 8 weeks post-MI. TIMP abundance dec-
reases significantly in the border region after MI, 
and TIMP-1, -2 and -3 fall to undetectable levels 
within the MI region. Similar results are obtained by 
the use of a pig model of MI [12]. These data clearly 
demonstrate that targeting of the regional imbalance 
between specific MMPs and TIMPs within the post-
MI myocardium holds a therapeutic potential. 
Galectin-3 is a β-galactoside–binding lectin sec-
reted by activated macrophages, which has gained 
interest as at least a marker of, or possibly even a 
potential mediator in inflammation and fibrosis, 
processes that are central to the pathophysiology of 
LV remodeling [6, 14, 16]. Tsai et al. suggested few 
important clinical implications of galectine-3: 1) cir-
culating galectine-3 was significantly higher in MI 
patients than in normal controls; 2) there were sig-
nificant positive correlations of high circulating 
galectine-3 to an advanced Killip score, unstable 
haemodynamics requiring inotropic support, ad-
vanced HF and a high CADILLAC risk score; 
3) elevated galectin-3 was proven to be a strong 
independent predictor of 30-day MACO (major ad-
verse clinical outcome) among patients with STEMI 
undergoing primary percutaneous interventions [16]. 
Though, Weir et al. had demonstrated that higher 
galectin-3 concentrations at baseline were signifi-
cantly associated with lower left ventricle ejection 
fraction (LVEF) at 24-week follow-up, although 
there was no significant relationship between ga-
lectin-3 and remodeling per se [6]. 
Zile et al. had demonstrated in one small series 
that galectin-3 levels were significantly elevated in 
cohort of patients with HF with HFpEF [14]. Galectin-
3 might provide an early warning marker for patients 
who are at risk for development of HF symptoms and 
may allow medical intervention. According to other 
animal and human studies, galectin-3 in addition to 
clinical and some studies have shown that galectin-3 
had independent prognostic value, even after correction 
for established risk factor such as age, sex, BNP level, 
renal function, and diabetes mellitus [7]. 
Prognostic value of galectin-3 levels in plasma 
appears to be much stronger in the subset of patients 
with HFpEF in comparison with HF with reduced 
ejection fraction (HFrEF) [8, 11, 13]. Also, base line 
levels of galectin-3 seem to be sufficient to predict 
outcome, because serial measurement did not in-
crease the prognostic yield [4, 7]. 
Aim of our study to evaluate the serum level of 
MMP-2, -9, galactin-3 and C-reactive protein (CRP) 
in postinfarction heart failure with preserved 
ejection fraction patients. 
MATERIALS AND METHODS 
Baseline study 
The study was conducted with approval from the 
Ethics committee at State Establishment «Dnipropet-
rovsk Medical Academy of Health Ministry of 
Ukraine» according to principles outlined in the Hel-
sinki declaration. 
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Patients (n=38) included aged 40 to 80 years, 29 
males and 9 females were diagnosed with (HFpEF), 
according to ESC guidelines (2016) [5], and their fun-
ctional class according to NYHA classification for HF. 
All patients got standard treatment for chronic heart 
failure (CHF) according to ESC guidelines 2016 [10]. 
Patients with acute myocardial infarction (˂6 
months), ejection fraction (EF) ≤40%, 2nd and 3rd 
degree heart block, diabetes mellitus (DM), 
kidney insufficiency (glomerular filtration rate: 
GFR≤30 ml/min/1.73m²), hepatic failure, and 
cancer were excluded.  
Standard laboratory blood tests for erythrocyte 
sedimentation rate, CRP, haematological parameters, 
lipid profile, glucose, renal and liver function tests 
were performed and calculated body mass index 
(BMI) for all patients. 
Gelatin zymography (mmp activity assay) 
The gelatinolytic activity was analyzed by sepa-
rating serum proteins (100 µg/track) on 7.5% SDS-
PAGE gels copolymerized with gelatin (3 mg/ml). 
After electrophoresis, the gels were washed twice 
for 30 min in gold 2.5% (v/v) Triton X-100 to re-
move SDS, and then 5 times for 5 min in cold bi-
distilled water. After washing, gels were incubated 
overnight at 37 °C in developing 50 mM tris-HCl 
buffer (pH 7.6), containing 0.15 M NaCl, 5 mM 
CaCl2, 1 mM ZnCl2, and 0.02% Tween-80. Zymo-
grams were stained with 0.11% Coomassie Briliant 
Blue R-250 solution in 30% methanol and 10% 
acetic acid and destained in the same solution lack of 
Coomassie Blue. The final gel had a uniform blue 
background except in those regions to which MMPs 
had migrated and cleaved the substrate. The gela-
tinolytic activity was identified as transparent bands 
against the background of Coomassie Blue-stained 
gelatine. The zymograms were visualized and ana-
lyzed densitometrically. 
All patients were assessed with galectin-3 blood 
levels by immunoassay analysis using the “Human 
Galectin-3 Platinum ELISA” kit (GmbH, Austria) on 
the Stat Fax 2100 (USA) immunoassay plate analy-
ser. The base level was taken as 0 ng/ml. 
Study design 
We divided all included patients into two main 
groups: 
1st group: 20 patients with HFpEF and history of 
myocardial infarction.  
2nd group: 18 patients with HFpEF and stable 
angina.  
T a b l e  1  
Baseline characteristics of the study population 
Characteristics 
Patients with CHF+MI 
in anamnesis 
(n=20) 




Males (%) 16 (80%) 13 (72%) Gender Females (%) 4 (20%) 5 (28%) 
Age, years    M±m 66±9 70±4 0,2106 
2nd FC 10 (50%) 11 (61%) CHFClass  according to 
NYHA 3rd FC 10 (50%) 7 (39%) 
Heart rate, beat/minute     M±m 74±5 77±4 0.137 
Body mass index (BMI)     M±m 28,00±2.10 30,00±2.50 0.202 
Blood glucose, mmol/L      M±m 5.45±0.20 5.15±0.25 0.337 
Cholesterol, mmol/L          M±m 5.50±1.60 4.95±0.25 0.048 
Тriglycerides, mmol/L       M±m 1.60±0.40 1.20±0.25 0.101 
ECHOCARDIOGRAPHY 
Left ventricle ejection fraction (EF), %                     
M±m 56.00±10.00 61.00±11.00 0.136 
Left ventricle end diastolic volume (LVEDV), ml                  
M±m 137.50±45.50 116.00±35.00 0.028 
Estimated Pulmonary artery pressure sPAP, mmHg            
M±m 30.01±9.12 28.24±7.14 0.547 
Treatment history, no, (%) 
Beta-blockers 16 (80%) 13 (72%) 
Renin angiotensin aldosterone system (RAAS) inhibitors 15 (75%) 14 (78%) 
Statins 17 (85%) 15 (83%) 
Acetylsalicylic acid (ASA) 19 (95%) 16 (88%) 
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RESULTS AND DISCUSSION 
Clinical characteristics of patients were sum-
marized in table 1. HFpEF patients with MI in 
anamnesis had significantly higher cholesterol level 
and left ventricle end diastolic volume (LVEDV)  
 
(p<0.05). There were no significant differences 
between the other indicators and treatment 
characteristics. 
 
T a b l e  2  
The level of MMP-2, MMP-9, galectin-3 in patients with HFpEF depending on MI anamnesis 
 1st group 2nd group р 
MMP-2 (ng/ml) M±m 78.00±18.00 61,00±16.00 0.002 
MMP-9 (ng/ml) M±m 217.50±21.50 172.50±6.50 0.003 
Galectin-3 (ng/ml) M±m 8.10±4.23 7.04±3.12 0.347 
 
It was established significant differences between 
study groups in MMP - 2, MMP-9 levels. Particular-
ly, HFpEF patients with MI in anamnesis had sig-
nificantly higher MMP-2, MMP-9 levels on 21.8% 
and 20.7% respectively. 
The CRP and leucocytes levels were significantly 
higher in 1st group pts. (fig.). 
Significant differences in MMP-2, MMP-9 were 
established in 1st group patients in different age 
groups (p<0.05) (tab. 3). The MMP-2 level was posi-
tively correlated with MMP 9 level (R=0.73, p<0.05), 
the MMP-9 level – with age (R=0.68, p<0.05). 
There were no significant differences between 
galectin-3 level in study group. But we estimated 
significant differences in galectin-3 level between 1st 
and 2nd subgroups (p<0.05) (tab. 3). 
While cytokines and MMPs have independent 
effects on the myocardium, past in vitro and animal 
studies have identified the ability of cytokines to 
regulate the transcription and synthesis of various 
MMPs. For example, TNF over-expression in mice 
led to increased protein levels of MMP-2 and -9 and 
TIMP-1 [4, 8, 11, 17]. Regulation of MMP synthesis 
includes several transcription factors that are do-
wnstream of cytokine signaling. Specifically, in 
fibroblasts, IL-1β stimulation has been reported to 
increase protein levels of MMP-2 and -9, which 
were attenuated with the inhibition of the trans-
cription factor NF-κB [11]. Similarly, IL-6 can in-
duce the expression of MMP-1 in macrophages me-
diated through transcriptional regulation of activator 
protein-1 and NF-κB [8]. By contrast, the anti-
inflammatory cytokine IL-10 suppressed MMP-2 
synthesis by signaling through the activating trans-
cription factor 3 and binding to the cAMP-res-
ponsive element of the MMP-2 gene [4].  
 
T a b l e  3  
The level of MMP-2, MMP-9, galectin-3 in patients with HFpEF in different age groups 
1st group 2nd group 
 
40-59 y.o. ≥ 65 y.o. 40-59 y.o. ≥ 65 y.o. 
MMP-2 (ng/ml) M±m 81.50±14.50* 85.50±8.50* 72.00±5.00 78.00±13.00 
MM-9 (ng/ml) M±m 212.50±16.50* 219.50±19.50* 172.5±6.50 175.00±4.00 
Galectin-3 (ng/ml) M±m 6.78±2.91 11.31±1.01# 6.21±2.29 9.95±0.22# 
N o t e s :  * – p< 0.05 between 1 and 2 groups, # – p<0.05 between 40-59 y.o. and ≥65 y.o. groups. 
 
Galectin-3 overexpression is also a characteristic 
feature of “profibrotic” M2 macrophages: naïve 
macrophages stimulated with interleukin-4 (IL-4) 
and IL-13 express higher levels of galectin-3, 
together with pathophysiology of diabetes mellitus 
type 1 by inducing β-cell apoptosis: mice β-cells 
from galectin-3 were resistant to inflammation-in-
duced cell death by counteracting mitochondrial 
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apoptotic pathways [6]. This is in contrast to 
previous research that demonstrated that intracellular 
galectin-3 supresses mitochondrial apoptotic path-
ways by preserving mitochondrial integrity [14]. 
In summary, the final outcome of the fibro-
inflammatory response is determined by a dynamic 
balance between neutrophil apoptosis, macrophage 
and T-cell responses, fibroblast activation and 
myofibroblast persistence, and intracellular galectin-
3 seems to be involved in many of these responses. 
However, our current understanding of galectin-3-
mediated apoptotic mechanisms is limited and 
further studies are warranted to characterize the role 
of intracellular galectin-3 in apoptosis of different 




N o t e .  * – p<0.05 
CRP, leucocytes levels in patients with HFpEF depending on MI in anamnesis 
  
Limitation 
In addition to the few number of patients inclu-
ded in this study, we excluded from our study pa-
tients with acute coronary artery diseases and acute 
heart failure, because of this our results apply only 
to the patients with chronic coronary artery diseases 
and chronic heart failure.  
There are many matrix metalloproteinases which 
involved in all cardiovascular diseases, but in our 
study we measured levels and activity of only MMP-
2 and MMP-9. 
CONCLUSION 
1. Serum MMP-2, MMP-9, CRP and galactin-3 
were significantly increased in pts with postin-
farction heart failure with preserved ejection fraction 
comparing to pts without myocardial infarction in 
anamnesis. 
2. Increased level of serum MMP-2, MMP-9, 
CRP were positively correlated with age reaching 
maximal concentration with age ≥65 years old in pts 
with postinfarction heart failure with preserved 
ejection fraction. 
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